Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma

This is a single center, single arm Phase Ib study with expansion cohort designed to establish the safety and physiologic effects of sirolimus pre-conditioning followed by T-cell engaging bispecific antibody therapy.

Trial Details

NCT ID

NCT07581704

Phase

PHASE1

Sponsor

Christopher Strouse

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

Sirolimus
Teclistamab
Talquetamb

Locations (sample)

Iowa City, Iowa, United States|41.66113,-91.53017

Key Eligibility Criteria

To be eligible to participate in this study, an individual must meet all of the following criteria:
Willingness and ability to provide signed and dated informed consent form.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Aged 18 years of older.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →